ABSTRACT
Introduction
Correctly diagnosing dementia type is increasingly important in an era when potentially diseasemodifying agents are soon likely to be marketed. Alzheimer's disease (AD) affects a range of cognitive domains including memory, executive functions, language and visuospatial function. Affected individuals show a range of impairment profiles across these functions, and these impairments may progress differently in each domain. Characteristically memory is affected early in AD (Grady et al., 1988; Welsh et al., 1991; Greene et al., 1996) and in severe AD all domains are affected (Price et al., 1993) . Atypical presentations of AD are, however, recognized and relate closely to the pattern of pathology at autopsy (Kanne et al., 1998; Galton et al., 2000) . Impairments of executive and language functions may be early prominent features of AD (Becker et al., 1988; Binetti et al., 1996; Gorno-Tempini et al., 2008) while behavioral abnormalities may also manifest early and have prognostic value (Stern et al., 1987; Mega et al., 1996) . A frontal variant of AD with a neuropathological correlate of greater numbers of neurofibrillary tangles within the frontal lobes than is seen in other AD patients is reported (Johnson et al., 1999) .
It can be difficult to distinguish AD patients with disproportionate frontal features from patients with frontotemporal dementia (FTD) -now known as frontotemporal lobar degeneration (FTLD) (Lebert et al., 1998; Storey et al., 2002) . The NINCDS-ADRDA diagnostic criteria for AD have low specificity when comparing AD with FTLD patients, where most FTLD patients can fulfill NINCDS-ADRDA criteria for AD (Varma et al., 1999) . Additionally, the Lund-Manchester clinical criteria for FTLD frequently misdiagnose AD, with 34% of clinically diagnosed AD cases in a community sample of 185 dementia cases fulfilling these non-AD criteria (Ikeda et al., 2004) . This clinical difficulty in diagnosis may reflect the underlying pathology, with 7-32% of patients clinically diagnosed as having FTLD found to have AD pathology alone or in combination with other pathology at autopsy (Kertesz et al., 2005; Knopmann et al., 2005; Forman et al., 2005; Knibb et al., 2006 ). An autopsy study of 45 well-characterized subjects with dementia had eight cases with both AD and FTLD pathology (Woodward et al., 2010a) and more recently the Alzheimer's Disease Neuroimaging Initiative reported that one of the first nine cases to come to autopsy had coexistent AD and FTLD (TDP-43) pathology (Cairns et al., 2010) . Patients with FTLD may have prominent early memory loss, further blurring the distinction between FTLD and AD (Hodges et al., 2004) . Indeed, it has been proposed that AD and FTLD are opposite ends of a spectrum with much overlap clinically, pathologically and genetically (Liscic et al., 2007; van der Zee et al., 2008) .
Several scales assess the cognitive profile of frontal executive function and neuropsychiatric symptoms referable to frontal structures. The Frontal Assessment Battery (FAB) (Dubois et al., 2000; Slachevsky et al., 2004) and the EXIT-25 (Royall et al., 1994) assess cognitive functions, particularly dysexecutive features, while the Frontal Behavioral Inventory (FBI) (Kertesz et al., 2000; Marczinski et al., 2004) and the Frontotemporal Behavior Scale (Lebert et al., 1998) assess neuropsychiatric ("behavioral") symptoms. It has previously been demonstrated that AD patients with greater frontal neuropsychiatric features as measured by higher FBI scores differ from AD cases with lower FBI scores across a range of features including cognition, function and behavior and more closely resemble subjects with FTLD in several of these features (Woodward et al., 2010b) . It was proposed in that study that these "high FBI AD" patients had frontal variant AD (FvAD), an AD syndrome variant based on clinical features.
We hypothesized that this proposed frontal variant of AD could also be clinically identified by lower scores on the FAB (indicating poorer executive function) and that these subjects would resemble FTLD subjects and both would differ from other AD subjects on a range of features including the degree of cognitive, behavioral and functional impairment, use of psychotropic medications, the degree of caregiver burden and the amount of change over 12 months.
Methods

PRIME (Prospective Research In MEmory clinics, NCT00297271
) is an ongoing non-prescriptive, longitudinal convenience cohort study. The primary purpose of PRIME is to provide a cohort of patients that can be examined to quantify complex relationships between a number of interrelated predictor and outcome variables. The study population is representative of Australian dementia patients treated by specialists, working in memory clinics and experienced in dementia management. A description of Australian memory clinics has been recently published (Woodward and Woodward, 2009 ( Petersen et al., 1999) ; were living in the community with fewer than 40 hours/week nursing care; had a caregiver willing to provide consent for required components of the study; were fluent in English; and could provide informed consent, or provision of written informed consent by a legal guardian/proxy was obtained. Clinicians utilized all available information to establish a diagnosis, including neuroimaging and neuropsychological assessments where available, and only initial diagnoses were utilized in this study. Patients were excluded if they had any concomitant life-threatening illness which was considered likely to interfere with the patient's ability to complete the study or if they were concurrently participating in a clinical trial of an investigational drug (phase I, II or III).
The following data were prospectively collected: baseline demographics and baseline, 6-and 12-monthly ratings on the Clinical Dementia Rating (CDR; Morris, 1993) ; Mini-mental State Examination (MMSE; Folstein et al., 1975 ); Alzheimer's Disease Assessment Scale -Cognitive (ADAS-Cog; Rosen et al., 1984) ; Functional Autonomy Measurement System (SMAF; Hebert et al., 1988) ; Neuropsychiatric Inventory (NPI; Cummings et al., 1994) ; Clock Drawing Test (Sunderland et al., 1989) ; Frontal Assessment Battery (FAB), and Zarit Caregiver Burden Interview (ZBI) (Bédard et al., 2001) . Instruments were recommended, but not required, to be completed at all visits. Only patients who had been enrolled for 12 months or more were included in this analysis.
For this analysis, patients were grouped by diagnosis. The first group of patients consisted of those with a diagnosis of FTLD as assessed by the clinician, using the Lund-Manchester criteria (Lund and Manchester Groups, 1994) . Patients with a diagnosis of AD were stratified by Frontal Assessment Battery (FAB) scores into two groups, with the quartile with the lowest FAB scores (i.e. reflecting greater executive dysfunction) nominated as the frontal variant Alzheimer's disease (FvAD) group, with the remainder called the AD group (Figure 1 ). Patients without a valid recorded baseline FAB score were included in the AD group. The data were also analyzed excluding those AD patients with missing FAB scores to determine the sensitivity of the findings to these AD cases with missing FAB scores.
To assess whether apparent differences between groups were reflecting differences in baseline severity, an additional analysis was conducted with the SMAF used as a marker of severity. Each FTLD subject was matched with four AD cases with the closest SMAF score, and these four cases were then removed from the pool of AD cases before the next FTLD case was matched. The AD cases were then arrayed on the basis of their FAB score, with the lowest quartile again nominated as the FvAD group. AD cases with missing FAB scores were excluded in this analysis.
Statistical analyses
All analyses were made pairwise between FTLD and FvAD, FvAD and AD and FTLD and AD groups respectively. Baseline demographics and assessments, six-month assessments and 12-month assessments, and the number of patients institutionalized at 12 months were all examined with Wilcoxon two sample tests or t-tests for continuous data and Fisher's exact test or χ 2 for categorical data. Wilcoxon two sample tests were performed upon the individual items of FAB at baseline for the FTLD and FvAD groups. Continuous variables are presented as mean (± standard deviation) and categorical variables are presented as (n(%)) unless otherwise stated. No a priori adjustments were made for multiplicity and significance was defined at the level of 0.05.
Results
At the time of this analysis, 523 patients with a diagnosis of AD and 31 patients with FTLD had Table 1 . Baseline demographics and assessments
. been enrolled in this study for at least 12 months. One subject with FTLD had no baseline SMAF and as the subject was excluded from the matchedseverity analysis the subject was also excluded from the initial analyses. The baseline demographics and assessments for the three groups, unmatched for severity, are presented in Table 1 along with the results of the pairwise comparisons between groups. In stratifying AD patients by baseline FAB scores, the 25th percentile fell between scores of 10 and 11. All patients with scores of 10 or less were included in the FvAD group.
The FvAD group had a similar age at both onset and baseline to the AD group but significantly differed from this group across all assessment scales, showing greater cognitive, functional, neuropsychiatric and global impairment and greater caregiver burden. The FTLD group more closely resembled the AD group than the FvAD group across all scales, differing significantly from the AD group in only the NPI and caregiver burden, where the mean scores of the FTLD group were in the direction of the FvAD group and away from that of the AD group.
Predictably, the FTLD patients were younger than both AD groups, and had a younger age at symptom onset. They did not resemble the FvAD group across most of the assessment scales, showing fewer frontal features (FAB), less cognitive and global impairment (MMSE, ADAS-Cog, Clock Drawing, CDR) and less functional impairment (SMAF). They did not significantly differ from the FvAD group in neuropsychiatric symptoms (NPI) but subjects with FTLD were associated with greater caregiver burden (Zarit) than subjects with FvAD and were more likely to be receiving psychotropic medication.
The changes in assessment scores and pairwise significance tests at six and 12 months are shown in Table 2 for each patient group. At six and 12 months, subjects with FTLD developed a significantly greater increase in frontal dysexecutive features than both the FvAD and AD groups, whose FAB scores remained relatively stable. There were also differences between the FTLD and FvAD groups at 12 months in the changes in the SMAF, where there was deterioration in both groups, but more so in the FvAD group. In all other scales the FTLD and FvAD groups showed similar changes at both six and 12 months. The FvAD group were found to deteriorate significantly more at six and 12 months than the AD group on most scales.
Apart from the FTLD group having a significantly greater decline in executive function at six and 12 months than the AD group, there were insignificant differences between these two groups at 12 months in the changes in the other scales. Only a small number of patients were institutionalized and the proportions were similar in both the FTLD and FVAD patient groups at both six months (two patients, 7.4% versus 11 patients, 12.0%, p = 0.73) and 12 months (cumulatively three patients, 11.5% versus 13 patients, 16.9%, p = 0.75). Statistically more FvAD patients were institutionalized at both six (11 patients, 12.0% versus 19 patients, 5.2% p = 0.032) and 12 months (13 patients, 16.9% versus 24 patients, 7.3% p = 0.014) compared with the AD group.
The reanalysis of the data excluding those AD cases with missing FAB scores showed little change from the results when these were included. Very few p values for differences between the groups moved over the 0.05 boundary, suggesting the results were not sensitive to the inclusion or exclusion of these patients. The major effect was in the changes over 6 and 12 months (shown in Table 2 ) where the significant differences between the FvAD and AD groups were attenuated, with the FvAD group no longer deteriorating significantly more than the AD group in MMSE and CDR at 6 months and ADAS-Cog and Clock drawing at 12 months.
When we analyzed the data matching for baseline dementia functional severity the FvAD group differed substantially from the AD group across most assessment scales, with the exception of the NPI and the Zarit, and was now much more similar to FTLD on all assessment scales except the MMSE and clock drawing (Tables 3 and 4) . As in the analysis not controlled for severity, the FAB score was lower for the FvAD group than for the FTLD group. The FvAD subjects differed from the FTLD group in being older and using fewer psychotropics but were similar to both the other groups on other baseline measures.
Over six and 12 months the matched FvAD group changed to a similar degree in most parameters as the other two groups except that these FvAD cases deteriorated more functionally and globally; they also deteriorated more cognitively than the AD group on the MMSE but not on the ADAS-Cog. The FTLD group was again found to deteriorate more on the FAB than the other two groups. Table 4 . Change from baseline in assessment scores at 6 and 12 months, matched for severity at baseline 
Discussion
Consistent with our hypothesis, we confirmed that a subset of AD patients with greater dysexecutive features differed substantially across a wide range of features from the rest of the subjects with AD. These subjects were more cognitively and functionally impaired, exhibited more behavioral symptoms and showed a greater decline on several measures over six and 12 months. Their greater neuropsychiatric morbidity was associated with greater caregiver burden. These differences were present despite the groups not differing significantly with respect to age, gender, marital status, family history of dementia, living arrangement, caregiver characteristics or use of psychotropic medication. The greater cognitive, functional and behavioral impairment was associated with a greater rate of institutionalization. These FvAD subjects also differed substantially from the FTLD group in most domains, with the exception of neuropsychiatric symptoms. The FTLD group more closely resembled the AD group than those with FvAD in all domains except age of onset, neuropsychiatric symptoms, use of psychotropics and caregiver burden. This is a surprising finding of this study as it was hypothesized that the frontal features of the FvAD group would make them similar to the FTLD group. Rather than define a discrete non-frontal AD group that differs from both the FvAD and FTLD groups, we have separated out an FvAD group that differs substantially from both the other groups. What is perhaps most remarkable is that in using just one measure of impairment, a lower score on the FAB, we have separated off a group of AD patients who significantly differ from the rest of AD patients in all other domains that were measured by an impairment scale (cognitive, functional, behavioral/neuropsychiatric and global).
This finding is at variance with the similar Canadian study (Woodward et al., 2010b ) that used a different frontal assessment scale -the FBI. In both studies the clinical features at enrolment were measured and utilized in the analyses. In the Canadian study the FTLD and the proposed FvAD groups were similar across several domains including function and neuropsychiatric symptoms but, as in this study they differed with respect to age of onset (younger for the FTLD group) and cognitive impairment (greater in the proposed FvAD group). On nearly all individual FBI items, the FTLD group and the FvAD group were very similar. In essence, the Canadian study showed that the most dissimilar of the three groups was the (non-frontal) AD group whereas we have demonstrated in this study that the most dissimilar group was the FvAD group.
A possible explanation for the varying findings from these two studies is that the FBI identifies frontal behavioral impairments whereas the FAB mostly identifies the cognitive dysexecutive features. As FTLD is frequently characterized by early behavioral changes, an FvAD subgroup defined by a scale measuring these behavioral changes could be expected to resemble the FTLD group. Our FTLD group was indeed more behaviorally disturbed than the other groups, as reflected in the higher NPI score, greater use of pychotropics and higher caregiver burden. Dysexecutive features are an early feature of AD but in FTLD these features often present later so an FvAD group defined by executive impairment could be expected to differ from the FTLD cases in earlier stages. In support of this, on the FAB our FTLD group declined far more at six and 12 months than the FvAD group and this greater degree of change was statistically significant at both time points. In essence, the FTLD group, which began with an almost identical FAB score to the (non frontal) AD group and indeed the whole AD group, was "catching up" with the FvAD group in their degree of executive dysfunction over the subsequent 12 months and leaving behind the AD group which was deteriorating far less in their FAB score. Thus, the concept that an FvAD group exists may not be disproven by our finding that this group did not initially resemble the FTLD group when FvAD is defined solely by executive dysfunction.
It does seem likely however that the FvAD groups defined by these two different approaches may not be similar groups. Further supporting this is the finding that the mean NPI scores of our FvAD group were lower than those of the FTLD group, suggesting less initial behavioral disturbance. In the Canadian study, the mean NPI scores of both the proposed FvAD group and the FTLD group were almost identical (29.8 and 29.0 respectively), and differed substantially from that of the other subjects with AD (8.3). Indeed, the mean NPI scores of the FTLD and FvAD groups in that study were higher than those of the FTLD subjects in our study (25.4) suggesting considerable behavioral disturbance in both groups in that study. Others have found that, for the same degree of dementia severity, subjects with FTLD have a greater degree of behavioral disturbance than those with AD (Mendez et al., 1998) .
Is there any clinical value in separating off this proposed FvAD group using a measure of executive dysfunction, as we have done? These patients would appear to differ enough, at least initially, from the FTLD subjects not to pose difficulties in the differential diagnosis between AD and FTLD. They were more impaired across most measures, older and less likely to be on psychotropic medications. Indeed, they seem far easier to differentiate from subjects with FTLD than do those AD cases with prominent early behavioral features (Woodward et al., 2010b) . Our findings suggest that where the differential diagnosis of AD and FTLD is being considered, prominent executive dysfunction in the absence of prominent behavioral impairments supports a diagnosis of AD, not FTLD. In essence, the early features of some cases of AD overlap with features of subjects with FTLD more in the behavioral domain than in the dysexecutive domain.
Our operationalization of FvAD may simply have led to the selection of subjects with more advanced AD. As AD progresses the characteristic neuropathology becomes more widespread, and can involve the frontal lobes (Braak and Braak 1991) . This could be expected to lead to more apparent frontal symptomatology. Our FvAD group had more impairment than the (remaining) AD group on all assessment scales but were not older at either entry into the study or age at onset of symptoms.
Our further analyses, where the AD and FTLD cases were matched for baseline severity, as measured by the SMAF, suggest that baseline severity may have affected the other characteristics of the two AD groups. Both groups are now marginally less affected on almost all parameters, suggesting the matching process eliminated mainly more severely affected cases which had been included before the matching. The biggest effect of this matching process however is that it created an FvAD group that look more like the FTLD than the AD group, differing less from the FTLD in most baseline assessment scale scores -insignificantly on many parameters when, post hoc, the p-values were adjusted for multiple comparisons. The FTLD and FvAD groups do differ in the degree of executive dysfunction and in two of the cognitive scales, the MMSE and the Clock-drawing score, the latter also reflecting executive function, but they did not differ on the ADAS-Cog. The FvAD group are still significantly more functionally impaired than the AD group. Their greater cognitive and functional impairment than both the other groups is interesting and suggests that cognitive, functional and executive impairment in the AD group may be linked. Thus, selecting a group that is more impaired on any of the scales will likely lead to the selection of a more severely impaired group of AD patients even when most severely impaired AD cases are excluded from the selection pool. The 6-and 12-month change data still show the FvAD group deteriorating more functionally and globally than the AD group, and the FTLD group deteriorating more on the FAB than both other groups-again supporting a "catch up" in the degree of executive dysfunction in a group that initially and surprisingly showed only as much executive dysfunction as the AD group.
On balance, our findings seem to indicate a greater disease burden in the FvAD group but they are also consistent with the FvAD group having a distinct clinical presentation characterized by prominent executive dysfunction but no difference in disease duration or age of onset to the other AD cases. The further severity-matched analysis has not changed this essential difference between the FvAD and the AD cases, or the similarity between the AD and FTLD groups, but has created an FvAD group that now looks more like FTLD and, as in the other study (Woodward et al., 2010b) still raises the possibility that there may be a frontal variant of AD that looks more like FTLD than AD.
We concede that there are limitations to our findings. There could have been selection bias in the administration of the FAB within the study as the protocol did not require all subjects to have all scales administered at all visits. We did identify 139 subjects who did not have the FAB administered at baseline. There is also clearly circularity in selecting FvAD cases according to a frontal dysexecutive score and then characterizing FvAD thus defined on this and other clinical measures. There is, however, justification for examining subjects at the statistical margins of any disease, rather than just the "average" patient. The circularity, however, and a limited availability of information around the presenting complaints of our FvAD cases and their longitudinal change prior to entry into our study limit the clinical validity of our observations. Additionally, we relied on clinical diagnosis to assign diagnostic categories, which may well have been incorrect in some cases. To somewhat offset this risk, the clinicians were working in centers of excellence with access to neuroimaging and other assessments, which have been shown to produce a diagnostic accuracy, when correlated with autopsy data, of around 90% (Lopez et al., 2000) . Penultimately, even matching the AD cases to the FTLD cases for baseline functional severity and then differentiating a subgroup with the lowest FAB scores made it difficult to differentiate the effects of severity from type as we again separated the most severely dementing AD cases. Lastly, there was no neuropathological confirmation of the clinical diagnoses presented in this study.
Notwithstanding these limitations, our data are consistent with the existence of a subgroup of AD patients with greater executive dysfunction who are probably a more severely affected group of those with AD and who do not initially have a strong clinical overlap with the subjects with FTLD, who had a greater degree of behavioral disturbance. It is only when baseline severity is matched that this FvAD group resembles the FTLD group, and such matching is impractical in the clinical setting. The study does encourage future prospective clinical studies aimed at the further characterization of FvAD, however defined, and investigations into the neuropathological basis of this proposed variant of AD. Clinicians should be cautious when assigning patients with dementia and behavioral or executive dysfunction to a diagnosis of either FTLD or AD. Clinical differentiation can be difficult and the future may lie in combining clinical assessment with other investigations such as biomarkers.
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